<DOC>
	<DOCNO>NCT03064867</DOCNO>
	<brief_summary>The purpose study determine correct dose safety add new cancer drug , venetoclax , standard combination chemotherapy drug second treatment relapsed/refractory DLBCL . In study , venetoclax add RICE ( rituximab , ifosfamide , carboplatin , etoposide ) , common set cancer drug use second line treatment relapsed/refractory DLBCL . Venetoclax , new target anti-cancer drug , work mimic particular protein produce tumor interrupt normal process , ultimately cause tumor cell die . Adding venetoclax standard RICE regimen believe increase chance get cancer remission . Venetoclax experimental approve Food Drug Administration ( FDA ) treatment relapsed/refractory DLBCL . Venetoclax FDA approve use patient chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Venetoclax Plus R-ICE Chemotherapy Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Primary Objective : Establishment safety V+RICE order identify recommend Phase II dose ( RPD2 ) Secondary Objectives : 1 . Determine overall response rate ( ORR ) V+RICE relative historical control RICE alone r/r DLBCL . 2 . Determine percent patient proceed autologous stem cell transplantation V+RICE relative historical control . 3 . Describe progression-free survival ( PFS ) overall survival ( OS ) patient treat V + RICE proceed auto-Stem Cell Transplant , relative historical control . 4 . Measure total number peripheral blood stem cell collect patient treat V + RICE proceed stem cell mobilization/harvesting , compare historical control .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histological confirmation relapsed/refractory diffuse large Bcell lymphoma prior rituximab anthracyclinecontaining systemic treatment regimen RCHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) , REPOCH ( rituximab , etoposide phosphate , prednisone , vincristine sulfate , cyclophosphamide , doxorubicin hydrochloride ) , RHyperCVAD ( rituximab , cyclophosphamide , vincristine sulfate , doxorubicin hydrochloride , dexamethasone ) etc . Subjects must receive 2 prior systemic therapy lymphoma . Prior therapy systemic rituximab monotherapy conventional chemotherapy ( i.e . bendamustine , CVP ( Cyclophosphamide , Vincristine Sulfate , Prednisone ) ) ± rituximab indolent nonHodgkin 's lymphoma ( NHL ) ± maintenance/extendeduse rituximab count 1 line systemic therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤ 2 Subjects must normal organ marrow function define : Hemoglobin ≥ 8.0 g/dl Absolute neutrophil count ≥ 1,000/mcL Platelet count ≥ 75,000/mcL Total bilirubin ≤ 1.5 X upper limit normal ( ULN ) unless know history impaired bilirubin conjugation Gilbert 's , maximum 2.5 ULN . Aspartate transaminase ( AST ) ( SGOT ) ≤ 2.5 X institutional ULN Alanine transaminase ( ALT ) ( SGPT ) ≤ 2.5 X institutional ULN International normalize ratio ( INR ) &gt; 1.5 ×ULN Patients must calculate serum creatinine clearance &gt; 50 mL/min use CockcroftGault calculation base 24hour urine collection perform within 7 day prior treatment . Specific guideline follow regard inclusion relapsed/refractory DLBCL base Hepatitis B serological test follow : HBsAg negative , HBcAb negative , HBsAb positive patient eligible . Patients test positive HBsAg ineligible Patients HBsAg negative , HBcAb positive ( regardless HBsAb status ) HBV DNA test perform protocol eligibility determine follow : If HBV DNA positive , subject ineligible . If HBV DNA negative , subject may include must undergo HBV DNA PCR test monthly x 3 month begin start treatment Subjects must ability understand willingness sign write informed consent document . For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method failure rate &lt; 1 % per year treatment period least 30 day last dose venetoclax 18 month last dose rituximab , whichever longer . A woman consider childbearing potential postmenarcheal , reach postmenopausal state ( &lt; 12 continuous month amenorrhea identify cause menopause ) , undergone surgical sterilization ( removal ovary and/or uterus ) . For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agreement refrain donate sperm , define : With female partner childbearing potential , men must remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 6 month last dose rituximab . Men must refrain donating sperm period . With pregnant female partner , men must remain abstinent use condom treatment period least 6 month last dose rituximab avoid expose embryo . Prior treatment toxicity resolve &lt; Grade 2 accord NCI CTCAE Version 4.0 ( except clinically insignificant toxicity alopecia ) . Subjects receive investigational agent . Patients active tumor lysis syndrome ( TLS ) either laboratory clinical change . Patients active central nervous system ( CNS ) disease define symptomatic meningeal lymphoma know CNS parenchymal lymphoma . History severe allergic reaction attribute compound similar chemical biologic composition rituximab agent use study . Subjects uncontrolled intercurrent illness . HIVpositive subject combination antiretroviral therapy ineligible potential pharmacokinetic interaction Venetoclax . In addition , subject increase risk lethal infection treat marrow suppressive therapy . Appropriate study undertaken subject receive combination antiretroviral therapy indicate . HIV test prior enrollment require screen strongly encourage patient document prior HIV assessment . Presence positive test result hepatitis B virus ( HBV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) antibody . Patients positive HCV antibody must negative HCV polymerase chain reaction ( PCR ) eligible study participation Patients occult prior HBV infection ( define positive total hepatitis B core antibody [ HBcAb ] negative HBsAg ) may include HBV DNA undetectable . These patient must willing undergo monthly DNA testing . Women pregnant lactate Malabsorption syndrome condition precludes enteral route administration Chemotherapy radiation within 3 week first schedule study treatment . Less 2year disease free another primary malignancy ( squamous basal cell carcinoma skin , `` insitu '' carcinoma cervix breast , superficial bladder carcinoma , previously treat localized prostate cancer normal prostate specific antigen ( PSA ) level ) . Patients complete anticancer treatment another primary malignancy 2 year prior screen eligible consider `` currently active '' malignancy base less 30 % risk relapse . Major surgery , diagnostic surgery , within 2 week . Medical condition require chronic use high dose systemic corticosteroid ( i.e. , dose prednisone high 10 mg/day equivalent ) . Brief ( &lt; 15 day ) treatment glucocorticoid ( prednisone 100 mg mouth daily , equivalent ) acceptable . Known allergy xanthine oxidase inhibitor rasburicase . Use warfarin prohibit . Anticoagulation lowmolecular weight heparin ( i.e . enoxaparin ) direct thrombin inhibitor permit . The following concomitant medication allow 7 day prior first dose study drug venetoclax administration : Strong CYP3A4 inhibitor include limited fluconazole , ketoconazole , clarithromycin strong CYP3A4 inducer include limited rifampin , carbamazepine . Receipt livevirus vaccine within 28 day prior initiation study treatment need livevirus vaccine time study treatment . Concomitant medication fall category could potentially lead adverse reaction consider cautionary . Moderate/Weak CYP3A inducer efavirenz oxcarbazepine CYP2C8 substrates thiazolidinediones ( glitazones ) select statin ( expect inhibition metabolism CYP2C8 substrates ) venetoclax CYP2C9 substrates tolbutamide ( expect inhibition metabolism CYP2C9 substrates venetoclax . It recommend exclude CYP2C9 substrates narrow therapeutic index phenytoin .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>venetoclax</keyword>
	<keyword>rituximab</keyword>
	<keyword>ifosfamide</keyword>
	<keyword>carboplatin</keyword>
	<keyword>etoposide</keyword>
</DOC>